Blood test may let some stomach cancer patients skip harsh chemo

NCT ID NCT07565857

Not yet recruiting Knowledge-focused Sponsor: Natera, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a personalized blood test (Signatera) can identify gastric cancer patients who, after surgery, have no detectable cancer DNA and can safely receive a milder immunotherapy (durvalumab) instead of standard chemotherapy. About 1000 adults with stage II-IVa gastric cancer will be enrolled. The goal is to see if this approach maintains similar cancer-free survival while reducing treatment side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Signatera blood test (ctDNA monitoring) and durvalumab (immunotherapy)
What this could lead to: If successful, this could show that some patients with gastric cancer can safely skip intensive chemotherapy after surgery, reducing side effects while maintaining similar outcomes.
What could go wrong: This is an early-stage study (Phase NA) with 1000 participants, and the approach may not prove non-inferior to standard care. The blood test may miss some recurrences, and durvalumab has its own risks like immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal adenocarcinoma Esophageal Neoplasms gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC/ESOPHAGEAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.